AI-guided precision therapy for active rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests a new, AI-powered treatment approach for rheumatoid arthritis. It's for people with active disease who haven't used certain biologic or targeted therapies in the last 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of rheumatoid arthritis (RA) based on the official 2010 criteria.
- Your arthritis must be moderately active or more (DAS28 score above 3.2).
- You must be at least 21 years old.
- You cannot have taken certain stronger RA medications (like Humira or Xeljanz) in the past 6 months.
- You cannot have a history of lymphoma or other cancers (except some skin cancers) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized exercise program designed by artificial intelligence for people with rheumatoid arthritis affecting their knees. It aims to improve knee function and reduce pain.
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
This study tests an oral drug called AP1189 for people just diagnosed with active rheumatoid arthritis who haven't yet taken standard arthritis medicines. You may be able to take part if your disease is very active and you're ready to try a new treatment option.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't improved after trying multiple treatments. It aims to see if the drug can reduce joint pain and swelling when other medications have failed.
This study follows different groups of people—from those at high risk of developing rheumatoid arthritis to those recently diagnosed—to learn more about the disease. By joining, you help researchers understand who gets RA and why, which may lead to earlier detection and better care.
This trial tests a new medicine called VDJ001 for people with moderate to severe rheumatoid arthritis who are already taking methotrexate. The goal is to see if VDJ001 helps reduce joint pain and swelling better than a placebo.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.